A Phase 3, Multicenter, Randomized, Double-Blind Study Comparing the Safety Efficacy of ABT-874 to Methotrexate in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Trial Profile

A Phase 3, Multicenter, Randomized, Double-Blind Study Comparing the Safety Efficacy of ABT-874 to Methotrexate in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Mar 2016

At a glance

  • Drugs Briakinumab (Primary) ; Methotrexate
  • Indications Plaque psoriasis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 08 Mar 2016 Results (n=849) of a pooled subgroup analysis from this and two other trials (see profile 40201 and 255049) presented at the 74th Annual Meeting of the American Academy of Dermatology
    • 08 Mar 2016 Results (pooled subgroup analysis of this and other 3 phase III studies, n = 1558) presented at the 74th Annual Meeting of the American Academy of Dermatology.
    • 06 Nov 2012 Planned number of patients changed from 250 to 375 as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top